The Australian biotech’s move is meant to boost cash on hand and add optional sources of value beyond ordinary equity sales. Reports have disclosed the agreement is a private placement of convertible preferred stock. Propanc’s ticker is PPCB.
According to reports, Propanc has yet to disclose any details on custody arrangements, valuation methods, or policies for managing potential losses in its crypto holdings.
Alongside the crypto plan, Propanc is continuing work on its lead therapy, known as PRP, a proenzyme-based treatment aimed at solid tumors and metastatic disease. According to company statements, the drug candidate is moving toward regulatory filings and the team expects to begin first-in-human (Phase One) trials in 2026.
The therapy remains at an early stage, which means clinical results will be the main driver of long-term value for patients and shareholders alike.
The move reflects a trend of smaller biotech companies seeking funding beyond traditional capital markets. A crypto treasury could provide additional assets and flexibility for the company.
At the same time, analysts note that it may introduce extra market, tax, and regulatory challenges. Reports indicate observers are monitoring how Propanc plans to manage the acquisition, storage, and accounting of its digital assets.
Featured image from Unsplash, chart from TradingView
